ResearcherGarvan Institute of Medical ResearchNo recent work listed

Nils Eling

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4711-1176; OpenAlex author ID A5004833953. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2015: 2 papers

Papers 2

Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Co-author DOI 10.18632/oncoscience.160 ↗
Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas. Co-author DOI 10.2174/1568009615666150512102957 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Marc Giry-Laterrière · 1 shared paper, 2015 · strength 0.06
- Paper Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas. DOI 10.2174/1568009615666150512102957 ↗
Lorraine A. Chantrill · 1 shared paper, 2015 · strength 0.06
- Paper Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas. DOI 10.2174/1568009615666150512102957 ↗
Andreia V. Pinho · 1 shared paper, 2015 · strength 0.06
- Paper Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas. DOI 10.2174/1568009615666150512102957 ↗
Nathan Ryan Brady · 1 shared paper, 2015 · strength 0.06
- Paper Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. DOI 10.18632/oncoscience.160 ↗
Ilse Rooman · 1 shared paper, 2015 · strength 0.06
- Paper Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas. DOI 10.2174/1568009615666150512102957 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.